Latest Conference Articles

Data from AAAAI 2023 suggests that gut microbial composition, function, and metabolic activity are implicated in the efficacy of peanut oral immunotherapy in children with peanut allergy.

In recent data presented at the AAAAI annual meeting, dupilumab was found to have outperformed both mepolizumab and omalizumab in FEV1 improvement for asthma patients.

Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.

Data presented at the AAAAI annual conference showed that delayed cutaneous reactions were more reported following Moderna COVID-19 vaccination than other vaccines.

New data presented at the AAAAI annual meeting showed that a significant number of patients recommended to be evaluated for drug allergy never completed their diagnostic tests.

Data presented at the AAAAI annual meeting showed that machine learning models had a high accuracy rate in penicillin allergy prediction, though researchers concluded that more data is needed before adoption.

Recent data, presented at the AAAAI annual meeting, showed that oral sesame desensitization through crushed seeds and tahini was efficacious and safe for pediatric patients.

In this interview segment at AAAAI, Altman went into a discussion on challenges to systems biology approaches for allergic disease.

A study presented at the AAAAI 2023 Annual Meeting shows over 80% of the 20 patients with chronic allergy symptoms report significant improvement in their allergy symptoms after 2 weeks of intranasal cleansing with NasoClenz.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

An interview featured Bird discussing data from his AAAAI annual meeting presentation on a new oral immunotherapy product for those with peanut allergies.

The study found that COVID-19-induced sensory distortion is a multifactorial syndrome with distinct phenotypes and can have long-term effects on sensory perception.

Data featured at the AAAAI 2023 Annual Meeting revealed that children with current or prior SARS-CoV-2 infection had more autoantibodies than healthy children.

In a presentation at the AAAAI 2023 Annual Meeting, new data suggested that treating early symptoms may be a viable strategy for preventing acute attacks in patients with hereditary angioedema (HAE).

New data presented at the 2023 AAAAI Annual Meeting indicated that infants with anaphylaxis had different symptoms from those who were older, with greater involvement in other areas.

In another recent HCPLive interview at AAAAI, Altman described examples of systems biology approaches to allergic disease and the importance of cross-disciplinary collaboration.

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

Altman spoke in a recent interview about the main takeaways from his AAAAI presentation, during which he discussed systems biology research into allergic diseases.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

According to data from the AAAAI 2023 Annual Meeting, individuals with food allergies face numerous barriers when managing their condition while flying, with only 15% receiving epinephrine.

In an interview regarding his AAAAI poster session, Dellon described a sub-analysis of new phase 3 trial data on dupilumab for eosinophilic esophagitis patients.

"We are looking at trying to satisfy a truly unmet medical need," Dr. David Dworaczyk says about the development of a new epinephrine nasal spray for anaphylaxis.

Dr. David Dworaczyk explains phase 3 data showing a single intranasal dose of epinephrine produced a higher and more prolonged plasma curve compared to an intramuscular 0.3 mg autoinjector.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.